Francesca Cossarini

Francesca Cossarini

Auto-generated profile, based on publicly available information

Francesca Cossarini

Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2022 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MUMathieu Uzzan
Mathieu Uzzan
JMJérôme Martin
Jérôme Martin
LMLuka Mesin
Luka Mesin
ALAlexandra E. Livanos
Alexandra E. Livanos
TCTomas Castro-Dopico
Tomas Castro-Dopico
SMSaurabh Mehandru
Saurabh Mehandru

19 April 2024 in Science Immunology
Verified
Journal Article
Closed access
PCPablo Canales-Herrerias
Pablo Canales-Herrerias
MUMathieu Uzzan
Mathieu Uzzan
ASAkihiro Seki
Akihiro Seki
RCRafael S. Czepielewski
Rafael S. Czepielewski
BVBram Verstockt
Bram Verstockt
SMSaurabh Mehandru
Saurabh Mehandru
Vedolizumab (VDZ) is a first-line treatment in ulcerative colitis (UC) that targets the α4β7- mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) axis. To determine the mechanisms of action of VDZ, we examined five distinct cohorts of patients with UC. A decrease in naïve B and T cells in the intestines and gut-homing (β7 + ) plasmablasts in circulation of VDZ-treated patients suggested that VDZ targets gut-associated lymphoid tissue (GALT). Anti-α4β7 blockade in wild-type and photoconvertible (KikGR) mice confirmed a loss of GALT size and cellularity because of impaired cellular entry. In VDZ-treated patients with UC, treatment responders demonstrated reduced intestinal lymphoid aggregate size and follicle organization and a reduction of β7 + IgG + plasmablasts in circulation, as well as IgG + plasma cells and FcγR-dependent signaling in the intestine. GALT targeting represents a previously unappreciated mechanism of action of α4β7-targeted therapies, with major implications for this therapeutic paradigm in UC.

9 September 2020 in medRxiv
Verified
Preprint
Open access
PDF file
ALAlexandra E. Livanos
Alexandra E. Livanos
DJDivya Jha
Divya Jha
FCFrancesca Cossarini
Francesca Cossarini
AGAna Silvia Gonzalez-Reiche
Ana Silvia Gonzalez-Reiche
MTMinami Tokuyama
Minami Tokuyama
SMSaurabh Mehandru
Saurabh Mehandru
Given that gastrointestinal (GI) symptoms are a prominent extrapulmonary manifestation of coronavirus disease 2019 (COVID-19), we investigated the impact of GI infection on disease pathogenesis in three large cohorts of patients in the United States and Europe. Unexpectedly, we observed that GI involvement was associated with a significant reduction in disease severity and mortality, with an accompanying reduction in key inflammatory proteins including IL-6, CXCL8, IL-17A and CCL28 in circulation. In a fourth cohort of COVID-19 patients in which GI biopsies were obtained, we identified severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) within small intestinal enterocytes for the first time in vivo but failed to obtain culturable virus. High dimensional analyses of GI tissues confirmed low levels of cellular inflammation in the GI lamina propria and an active downregulation of key inflammatory genes including IFNG, CXCL8, CXCL2 and IL1B among others. These data draw attention to organ-level heterogeneity in disease pathogenesis and highlight the role of the GI tract in attenuating SARS-CoV-2-associated inflammation with related mortality benefit.

5 September 2020 in medRxiv
Verified
Preprint
Open access
PDF file
GBGraham Britton
Graham Britton
ACAlice Chen-Liaw
Alice Chen-Liaw
FCFrancesca Cossarini
Francesca Cossarini
ALAlexandra E. Livanos
Alexandra E. Livanos
MSMatthew P. Spindler
Matthew P. Spindler
JFJeremiah J. Faith
Jeremiah J. Faith
Background and aims: Immune dysregulation caused by SARS-CoV-2 infection is thought to play a pathogenic role in COVID-19. SARS-CoV-2 can infect a variety of host cells, including intestinal epithelial cells. We sought to characterize the role of the gastrointestinal immune system in the pathogenesis of the inflammatory response associated with COVID-19. Methods: We measured cytokines, inflammatory markers, viral RNA, microbiome composition and antibody responses in stool and serum samples from a prospectively enrolled cohort of 44 hospitalized COVID-19 patients. Results: SARS-CoV-2 RNA was detected in stool of 41% of patients and was found more frequently in patients with diarrhea than those without (16[44%] vs 5[19%], p=0.06). Patients who survived had lower median viral genome copies than those who did not (p=0.021). Compared to uninfected controls, COVID-19 patients had higher median fecal levels of IL-8 (166.5 vs 286.5 pg/mg; p=0.05) and lower levels of fecal IL-10 (678 vs 194 pg/mg; p<0.001) compared to uninfected controls. Stool IL-23 was higher in patients with more severe COVID-19 disease (223.8 vs 86.6 pg/mg; p=0.03) and we find evidence of intestinal virus-specific IgA responses, which was associated with more severe disease. Fecal cytokines and calprotectin levels were not correlated with gastrointestinal symptoms or with the level of virus detected. Conclusions: Although SARS-CoV-2 RNA was detectable in the stools of COVID-19 patients and select individuals had evidence for a specific mucosal IgA response, intestinal inflammation was limited, even in patients presenting with gastrointestinal symptoms.

24 May 2018 in AIDS and Behavior
Verified
Journal Article
Closed access
PDF file
FCFrancesca Cossarini
Francesca Cossarini
DHDavid B. Hanna
David B. Hanna
MGMindy S. Ginsberg
Mindy S. Ginsberg
OBOni J. Blackstock
Oni J. Blackstock
KAKathryn Anastos
Kathryn Anastos
UFUriel R. Felsen
Uriel R. Felsen

25 October 2024 in Science Immunology
Verified
Journal Article
Closed access
FCFrancesca Cossarini
Francesca Cossarini
JSJoan Shang
Joan Shang
AKAzra Krek
Azra Krek
ZAZainab Al-Taie
Zainab Al-Taie
RHRuixue Hou
Ruixue Hou
SMSaurabh Mehandru
Saurabh Mehandru
Gastrointestinal (GI) B cells and plasma cells (PCs) are critical to mucosal homeostasis and the host response to HIV-1 infection. Here, high-resolution mapping of human B cells and PCs sampled from the colon and ileum during both viremic and suppressed HIV-1 infection identified a reduction in germinal center (GC) B cells and follicular dendritic cells (FDCs) during HIV-1 viremia. Immunoglobulin A–positive (IgA + ) PCs are the major cellular output of intestinal GCs and were significantly reduced during viremic HIV-1 infection. PC-associated transcriptional perturbations, including type I interferon signaling, persisted in antiretroviral therapy (ART)–treated individuals, suggesting ongoing disruption of the intestinal immune milieu during ART. GI humoral immune perturbations were associated with changes in the intestinal microbiome composition and systemic inflammation. These findings highlight a key immune defect in the GI mucosa due to HIV-1 viremia.